FAQ/Help |
Calendar |
Search |
Today's Posts |
|
![]() |
#1 | |||
|
||||
Magnate
|
See? This is why you guys rock!
|
|||
![]() |
![]() |
![]() |
#2 | |||
|
||||
Senior Member
|
I was first going to say that it sounded a lot like some people's sex lives, but that's really WAY COOL if it works and they get it approved!
![]() I'd shoot up 2x a year. Keep us posted about it please!
__________________
A Hairy Chicken Is Better Than A Hairy Hand! |
|||
![]() |
![]() |
"Thanks for this!" says: |
![]() |
#3 | |||
|
||||
Fabulous Belizean Member
|
hot off the wire, a Bloomberg Exclusive:
BioMS May Give Lilly $5 Billion Cure for Expiring Drug Patents By Kelly Riddell Dec. 26 (Bloomberg) -- BioMS Medical Corp., a one-drug biotechnology company in Edmonton, Alberta, may hold a partial answer as to how Eli Lilly & Co. will replace $9.9 billion in sales threatened by expiring patents. Lilly signed a $497 million licensing and development agreement for BioMS’s dirucotide, potentially the first treatment for advanced forms of multiple sclerosis to come to market. The medicine, which entered final trials, has so far escaped side effects such as influenza-like symptoms, fatigue and skin cancer that were reported by Basel, Switzerland-based Novartis AG on fingolimod, another late-stage drug in testing for the disease. A mid-level study of dirucotide, involving 218 subjects, had “very impressive features to it,” according to Bill Chin, Lily’s vice president of discovery and clinical investigation. The drug represents a chance for “a breakthrough,” he said. http://www.bloomberg.com/apps/news?p...ZNs&refer=home
__________________
And the trouble is... if you don't risk anything, you risk even more. - Erica Jong |
|||
![]() |
![]() |
Reply |
|
|
![]() |
||||
Thread | Forum | |||
January is another year and hopefully a year of SUCCESS for us! :) | Weight Loss & Healthy Living | |||
New PM Dr. = New Meds | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
Jim “Catfish” Hunter Chapter Named Chapter of the Year for Second Year in a Row | ALS News & Research |